The average one-year price target for Werewolf Therapeutics (NasdaqGS:HOWL) has been revised to $5.30 / share. This is a ...

Werewolf Therapeutics, Inc. develops modified cytokines for cancer treatment, including WTX-124, a modified IL-2, and WTX-330, a modified IL-12. Xilio Therapeutics out-licensed their modified IL-12 to ...

HOWL reported interim data in November from its phase 1/1b trial of WTX-124 in solid tumors. There are signs of antitumor activity at the 12 mg dose of WTX-124, with two unconfirmed partial responses ...

Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Werewolf Therapeutics (HOWL – Research Report) yesterday and set a price target of $9.00. The company’s shares closed ...

Howling II: Stirba – Werewolf Bitch is a horror-indie film based on Gary Brandner’s novel titled “The Howling II.” In the movie, a man discovers his sister was a werewolf during her funeral. Shocked ...

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) is anticipated to issue its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect the company to announce ...

Horror has a plethora of subgenres, from slashers and zombies, to ghosts and vampires, and many more. An underappreciated subgenre is the werewolf film. Although there were classics like The Wolfman ...

A cinematic obsessive with the filmic palate of a starving raccoon, Rob London will watch pretty much anything once. With a mind like a steel trap, he's an endless fount of movie and TV trivia, borne ...